A second Carl Icahn protégé jumps in on SPAC spree, as Alex Denner guns for $175M

A second Carl Icahn protégé is jumping into the biotech SPAC rush, this time one with a lot more experience — and a lot more of a reputation — in drug development.

Alex Denner, the managing partner at Sarissa Capital and architect of activist attacks at a handful of major biotechs over the last decade, has filed to raise $175 million of a specialty acquisition company that would focus on “healthcare and biopharma,” with cell and gene therapy garnering particular emphasis in the S-1.  The SPAC will be known as Sarissa Capital Acquisition.